Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast as Add-on Therapy for Chronic Urticaria
NCT07850843Phase 2Enrolling by invitation
- Sponsor
- Rashid Latif Medical College
- Start
- Sep 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 2, open-label trial of apremilast in chronic urticaria (CU) (2 arms), sponsored by Rashid Latif Medical College. Primary endpoint: Change in weekly Urticaria Activity Score at 12 weeks. Started Sep 2026; status: enrolling by invitation.
02
Drugs
apremilast
03
Conditions
chronic urticaria (CU)
Beyond the preview
Go deeper on NCT07850843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07850843.